Current and emerging treatment modalities for metastatic castration-resistant prostate cancer

BJU International

Volumn 107, Issue SUPPL. 2, 2011, Pages 13-20

  Bracarda, Sergio ^a   Logothetis, Christopher ^b   Sternberg, Cora N ^c,d   Oudard, Stéphane ^d  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF TEXAS   (United States)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ATRASENTAN; BEVACIZUMAB; CABAZITAXEL; CALCITRIOL; CUSTIRSEN; DASATINIB; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; LENALIDOMIDE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; PROVENGE; SATRAPLATIN; SOMATOSTATIN DERIVATIVE; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; VIRUS VACCINE; ZIBOTENTAN; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DISEASE MARKER; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETREATMENT; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; EPIDEMIOLOGIC METHODS; HUMANS; IMMUNOTHERAPY; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PREDNISONE; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETREATMENT; TAXOIDS; TREATMENT OUTCOME;

EID: 79952513499     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10036.x     Document Type: Article

References (75)

1. Basch EM, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007; 25: 5313-8 (Pubitemid 350232264)
2. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. EAU 2009 ()
3. Horwich A, Parker C, Kataja V,. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 76-8
4. Mohler J, Babaian RJ, Bahnson RR, et al. Prostate cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007; 5: 650-83
5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
7. Lin AM, Ryan CJ, Small EJ,. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 2007; 61: 243-54 (Pubitemid 46329430)
8. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008; 112: 326-30
9. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-63 (Pubitemid 47106144)
10. Eymard JC, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 2010; 106: 974-8
11. Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J, Glaholm J,. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008; 20: 891-6
12. Fitzpatrick JM, Sternberg CN, Fred Saad F, et al. Treatment decisions for advanced genitourinary cancers: from symptoms to risk assessment. Eur Urol Supplements 2009; 8: 738-46
13. Noguchi S,. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006; 97: 813-20 (Pubitemid 44151259)
14. Sanchez C, Mendoza P, Contreras HR, et al. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 2009; 69: 1448-59
15. Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M,. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int 2008; 102: 622-7
16. Erten C, Karaca B, Kucukzeybek Y, et al. Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int 2009; 104: 107-14
17. Caffo O, Sava T, Comploj E, et al. Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int 2008; 102: 1080-5
18. Caffo O, Sava T, Comploj E, et al. Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol 2010; 28: 152-6
19. Fizazi K, Sikes CR, Kim J, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 2004; 24: 2897-903 (Pubitemid 39407164)
20. Oudard S, Legrier ME, Boye K, et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169: 1729-34 (Pubitemid 36443482)
21. Fizazi K, Le Maitre A, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol 2007; 8: 994-1000 (Pubitemid 47629887)
22. Figg WD, Li H, Sissung T, et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int 2007; 99: 1047-55 (Pubitemid 46587914)
23. Mackler NJ, Pienta KJ, Dunn RL, et al. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. Clin Genitourin Cancer 2007; 5: 318-22 (Pubitemid 47271780)
24. Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26: 5936-42
25. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME,. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008; 180: 565-70 (Pubitemid 351942412)
26. Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004; 63: 1138-42 (Pubitemid 38746819)
27. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233-40 (Pubitemid 41003711)
28. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003; 61: 774-80 (Pubitemid 36384972)
29. Pettaway CA, Pisters LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000; 18: 1050-7 (Pubitemid 30123782)
30. Shepard DR, Dreicer R, Garcia J, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009; 181: 1672-7
31. Eastham JA, Kelly WK, Grossfeld GD, Small EJ,. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003; 62 (Suppl. 1): 55-62 (Pubitemid 41116563)
32. Efstathiou E, Logothetis CJ,. A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res 2010; 16: 1100-7
33. Li ZG, Mathew P, Yang J, et al. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 2008; 118: 2697-710
34. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-33
35. Fizazi K., The role of Src in prostate cancer. Ann Oncol 2007; 18: 1765-73 (Pubitemid 350119560)
36. Attard G, Cooper CS, de Bono JS., Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009; 16: 458-62
37. Zurita AJ, Ward JF, Araujo JC, et al. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 2008; 26 (May 20 Suppl): Abstract 16004
38. George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932-6 (Pubitemid 32994827)
39. Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002; 8: 3226-31 (Pubitemid 35155035)
40. Kelly WK, Halabi S, Carducci MA, et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J Clin Oncol 2010; 28 (Suppl): Abstract LBA4511
41. Verheul HM, Hammers H, van Erp K, et al. Vascular endothelial growth factor Trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007; 13: 4201-8 (Pubitemid 47105984)
42. Dredge K, Horsfall R, Robinson SP, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56-63 (Pubitemid 40410468)
43. Bartlett JB, Dredge K, Dalgleish AG,. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314-22 (Pubitemid 38525287)
44. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-9
45. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009; 55: 1112-23
46. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010; 106: 966-73
47. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276: 473-81 (Pubitemid 126660483)
48. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9 (Pubitemid 41507982)
49. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-8
50. Hofbauer LC, Schoppet M,. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-5 (Pubitemid 38988958)
51. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA,. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006; 107: 289-98 (Pubitemid 44036558)
52. Gleave M, Chi KN,. Knock-down of the cytoprotective gene, clusterin, to enhance hormone and chemosensitivity in prostate and other cancers. Ann N Y Acad Sci 2005; 1058: 1-15
53. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME,. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50: 179-88 (Pubitemid 34137445)
54. Miyake H, Nelson C, Rennie PS, Gleave ME,. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 2000; 60: 170-6 (Pubitemid 30058748)
55. Chi KN, Hotte SJ, Yu E, et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer J Clin Oncol 2009; 27 (Suppl): Abstract 5012
56. Kantoff P, Higano CS, Berger ER, et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC). 2010 Genitourinary Cancers Symposium 2010; Abstract 8
57. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1099-105
58. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009; 27: 5431-8
59. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progress after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54
60. Bissery MC,. Preclinical evaluation of new taxoids. Curr Pharm Des 2001; 7: 1251-7
61. Vrignaud P, Lejeune P, Chaplin D, Lavelle F, Bissery MC,. In vivo efficacy of TXD258, a new taxoid, against human tumor xenografts. Proceedings AACR 2000; 41: 214
62. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-8
63. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71
64. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-95
65. de Bono JS, Logothetis C, Fizazi K, et al. Abiraterone acetate plus low dose prednisone improves overall survival in patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study. ESMO 35th Annual Meeting 2010
66. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90
67. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B,. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 2004; 93: 297-302 (Pubitemid 38253573)
68. Yildiz E, Gokce G, Kilicarslan H, Ayan S, Goze OF, Gultekin EY,. Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int 2004; 93: 1087-93 (Pubitemid 38758639)
69. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403 (Pubitemid 350075029)
70. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI,. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-7
71. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-8 (Pubitemid 350276887)
72. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-9
73. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233-9
74. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74 (Pubitemid 32878711)
75. van de Vijver MJ, He YD, van't Veer LâJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009 (Pubitemid 35461656)